AI Article Synopsis
- This study compares the effectiveness and safety of Atezolizumab plus Bevacizumab (ATEZO/BEVA) versus Lenvatinib (LEN) as first-line treatments for hepatocellular carcinoma (HCC).
- A total of 810 patients were analyzed, and after matching for comparable characteristics, the results showed no significant difference in objective response rates (44.8% for ATEZO/BEVA vs. 46.7% for LEN), but ATEZO/BEVA had better progression-free survival and overall survival rates.
- ATEZO/BEVA also had lower rates of severe side effects like appetite loss and fatigue, but a higher rate of severe bleeding, and showed a better conversion
Article Abstract
Background: A comparison between atezolizumab plus bevacizumab (ATEZO/BEVA) and lenvatinib (LEN) for the treatment of hepatocellular carcinoma (HCC) remains unclear.
Objective: This study aimed to compare the therapeutic effects and safety of ATEZO/BEVA and LEN as first-line therapies for HCC.
Patients And Methods: This study was a retrospective analysis of 810 patients with HCC who underwent ATEZO/BEVA (n = 186) or LEN (n = 624) as first-line systemic therapy between March 2018 to March 2022 at 14 facilities. After propensity score matching, 304 patients (ATEZO/BEVA group: n = 152; LEN group: n = 152) were analyzed.
Results: After propensity score matching, although there was no significant difference in objective response rates (ORRs) between the ATEZO/BEVA and LEN groups (ORR 44.8% vs. 46.7%, p = 0.644), the median progression-free survival (PFS) and median overall survival (OS) in the ATEZO/BEVA group were significantly higher than those in the LEN group (median PFS: 8.3 months vs. 6.0 months, p = 0.005; median OS: not reached vs. 20.2 months, p = 0.039). The rates of appetite loss, fatigue, and proteinuria of grade 3 or higher in the ATEZO/BEVA group were lower than those in the LEN group. However, the rate of bleeding of grade 3 or higher in the ATEZO/BEVA group was higher than that in the LEN group. The conversion rate was higher in the ATEZO/BEVA group than that in the LEN group (8.6% vs. 1.9%, p = 0.007).
Conclusions: ATEZO/BEVA showed superiority to LEN in terms of prognosis and conversion rate as first-line therapy. Moreover, ATEZO/BEVA had a lower rate of severe adverse events, except for bleeding, than LEN.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684293 | PMC |
| http://dx.doi.org/10.1007/s11523-022-00921-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The emerging therapies are reshaping the first-line treatment for advanced hepatocellular carcinoma: a systematic review and network meta-analysis.
Therap Adv Gastroenterol
April 2024
Department of Liver Surgery, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, Guangdong 510060, P. R. China.
Background: Given the superior performance of various therapies over sorafenib in advanced hepatocellular carcinoma (HCC) and the absence of direct comparisons, it is crucial to explore the efficacy of these treatments in phase III randomized clinical trials.
Objectives: The goal is to identify which patients are most likely to benefit significantly from these emerging therapies, contributing to more personalized and informed clinical decision-making.
Design: Systematic review and network meta-analysis.
The Analysis of Muscle Volume Measured by Bioelectrical Impedance in Patients with Hepatocellular Carcinoma Treated with First-Line Atezolizumab plus Bevacizumab Combination Therapy or First-Line Lenvatinib.
Oncology
August 2023
Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Article Synopsis
- The study investigates how skeletal muscle changes during treatment with atezolizumab plus bevacizumab (Atezo + Beva) or lenvatinib (Len) relate to prognosis in patients with hepatocellular carcinoma (HCC).
- It found that while the arm skeletal muscle index (SMI) decreased in patients receiving Len, it remained stable in those treated with Atezo + Beva.
- Additionally, factors like arm SMI and extracellular water to total body water ratio (ECW/TBW) were significant indicators of progression-free survival in the Len group.
Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real-world data.
Hepatol Res
February 2023
Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
Aim: Few studies have reported the efficacy and safety of ramucirumab (RAM) after atezolizumab plus bevacizumab (Atezo/Beva) treatment and the overall associated outcomes. Thus, we aimed to evaluate the therapeutic effects and safety of RAM post-treatment with Atezo/Beva.
Methods: This retrospective study enrolled 46 patients with unresectable hepatocellular carcinoma who were treated with RAM.
Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
Target Oncol
November 2022
Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Article Synopsis
- This study compares the effectiveness and safety of Atezolizumab plus Bevacizumab (ATEZO/BEVA) versus Lenvatinib (LEN) as first-line treatments for hepatocellular carcinoma (HCC).
- A total of 810 patients were analyzed, and after matching for comparable characteristics, the results showed no significant difference in objective response rates (44.8% for ATEZO/BEVA vs. 46.7% for LEN), but ATEZO/BEVA had better progression-free survival and overall survival rates.
- ATEZO/BEVA also had lower rates of severe side effects like appetite loss and fatigue, but a higher rate of severe bleeding, and showed a better conversion
Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study.
Cancers (Basel)
September 2022
Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan.
This study aimed to evaluate the correlation between adverse events (AEs) and overall survival (OS) in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab (atezo/beva). This was a multicenter study in which 130 patients were enrolled. Hypertension and skin disorders had a significant correlation with longer survival (median survival time (MST): not reached vs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!